BRAFV600E突变转移性结直肠癌原发灶部位与一线抗EGFR/抗VEGF疗效汇总分析
该汇总分析纳入七项AIO一线研究中的209例BRAFV600E突变且RAS野生型mCRC患者,比较抗EGFR与抗VEGF治疗的疗效。左半原发肿瘤患者抗EGFR治疗显示数值上OS获益,而右半原发肿瘤患者抗VEGF治疗PFS和OS更优。
要点
- BRAFV600E突变mCRC左半原发者抗EGFR治疗有OS数值获益趋势。
- 右半原发者抗EGFR治疗PFS显著劣于抗VEGF,OS亦劣。
- 总体人群抗EGFR治疗PFS显著缩短,OS无差异。
核心结论
- BRAFV600E突变mCRC左半原发肿瘤患者可从抗EGFR或抗VEGF定向抗体治疗中获得生存获益,而右半原发肿瘤患者未观察到此效应,且更受益于贝伐珠单抗。
研究设计与样本
- 对七项AIO一线研究(FIRE-3、FIRE-4、FIRE-4.5、CIOX、XELAVIRI、PANAMA、VOLFI)中BRAFV600E突变且RAS野生型mCRC患者进行个体数据汇总分析。
- 共209例可评估患者,左半原发肿瘤98例(46.9%),右半原发肿瘤111例(53.1%)。
主要发现
- 总体人群中,抗EGFR组与抗VEGF组ORR相当(OR 0.85;95%CI 0.47-1.52)。
- 总体人群中,抗EGFR组中位PFS显著更短(HR 1.42;95%CI 1.05-1.91;P=0.022),OS无显著差异(HR 0.96;95%CI 0.70-1.32;P=0.80)。
- 左半原发肿瘤患者中,抗EGFR组与抗VEGF组PFS相当(HR 0.98;95%CI 0.63-1.51),但OS有数值上获益(HR 0.71;95%CI 0.45-1.14),该效应独立于性别。
- 右半原发肿瘤患者中,抗EGFR组PFS更差(HR 2.09;95%CI 1.35-3.22;P<0.001),OS亦更差(HR 1.31;95%CI 0.84-2.05),男性和女性患者中均观察到该效应。
临床怎么用
- 对于BRAFV600E突变且RAS野生型mCRC,一线治疗选择抗EGFR或抗VEGF抗体时应考虑原发肿瘤部位。
- 左半原发肿瘤患者可考虑含抗EGFR抗体的方案,右半原发肿瘤患者则更倾向含贝伐珠单抗的方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both BRAFV600E-mutation and right-sided primary tumor location (PTL), have been associated with poor prognosis in metastatic colorectal cancer (mCRC). The present pooled analysis of individual patient data evaluates the efficacy of first-line chemotherapy combined with anti-EGFR- or anti-VEGF-directed therapy in BRAFV600E-mut mCRC together with PTL. METHODS: We conducted a pooled analysis of seven first-line AIO-studies (FIRE-3, FIRE-4, FIRE-4.5, CIOX, XELAVIRI, PANAMA, VOLFI) including patients with BRAFV600E-mut and RAS-wild-type mCRC. RESULTS: Among 209 evaluable patients, left-sided primary tumors (LSPT) were observed in 98 (46.9 %) compared to 111 (53.1 %) patients with right-sided primary tumors (RSPT). In the overall cohort, ORR was comparable (OR 0.85; 95 % CI 0.47-1.52), while median PFS was significantly shorter in patients receiving anti-EGFR-based therapy (HR 1.42; 95 % CI 1.05-1.91; P = 0.022), no major difference was observed with regard to OS (HR 0.96; 95 % CI 0.70-1.32; P = 0.80). Patients with LSPT showed comparable PFS (HR 0.98; 95 % CI 0.63-1.51), but a numerical OS benefit (HR 0.71; 95 % CI, 0.45-1.14) with anti-EGFR- compared to anti-VEGF-based therapy. This effect was observed independent of sex. In contrast, patients with RSPT showed both, inferior PFS (HR 2.09; 95 % CI 1.35-3.22; P < 0.001) and OS (HR 1.31; 95 % CI, 0.84-2.05). These effects were observed in male and female patients. CONCLUSIONS: The present analysis of BRAFV600E-mut mCRC suggests a survival benefit from anti-EGFR- or anti-VEGF-directed antibodies in patients with LSPT. This effect was not observed in RSPT, where patients showed a clearly greater benefit from bevacizumab.
引用
- Weiss L, Stintzing S, Modest DP, et al. First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group). Eur J Cancer. 2025. PMID: 41240527. doi:10.1016/j.ejca.2025.116105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。